BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11791126)

  • 1. Aromatase and aromatase inhibitors.
    Toi M; Bando H; Saji S
    Breast Cancer; 2001; 8(4):329-32. PubMed ID: 11791126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H; Gershanovich M
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
    Allred DC; Baum M; Buzdar AU; Carlson RW; Dowsett M; Elledge RM; Gradishar WJ; Grana G; Howell A; Mamounas EP
    Breast J; 2003; 9(3):213-22. PubMed ID: 12752630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Hamilton A; Piccart M
    Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of aromatase inhibitors in the treatment of breast cancer.
    Choueiri TK; Alemany CA; Abou-Jawde RM; Budd GT
    Clin Ther; 2004 Aug; 26(8):1199-214. PubMed ID: 15476902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
    Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB
    Am J Health Syst Pharm; 2005 Feb; 62(3):266-73. PubMed ID: 15719584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings.
    Ingle JN; Suman VJ
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):313-9. PubMed ID: 14623527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.